Skip to main content

Share story

Infrastructure

QCi Quantum Optimization Machine placed on Quantum Corridor network

HAMMOND, Ind. and HOBOKEN, N.J. Quantum Corridor and Quantum Computing Inc. announced the placement of a Dirac-3 quantum optimization machine on the Quantum Corridor network. The machine was deployed at the Digital Crossroad Data Center in Hammond, Ind. This marks the first data center installation of a Dirac-3 machine and the first such installation in a commercial data center environment. The partnership allows enhanced customer access with secure, on-demand access to the Dirac-3 over the network. The connection is secured with Toshiba Quantum Key Distribution over the 10G commercial fiber infrastructure. Dr. Yuping Huang, CEO of QCi, said the collaboration delivers the first data center installation and enhances secure and scalable access to quantum computing capabilities. It expands practical access for academic and enterprise users in the region. Dr. Mit Jha, CEO of Quantum Corridor, said the network now provides customers with access to computing solutions that can solve previously intractable optimization problems. The Dirac-3 supports applications such as fraud detection across millions of transactions, optimization of complex portfolios, planning of mission critical operations and management of UAS risk at scale.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Quantum Computing Inc and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.